Abbas S, Bissett I P, Parry B R
University of Auckland, Surgery, Parks Road, Auckland, New Zealand.
Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD004651. doi: 10.1002/14651858.CD004651.pub3.
Adhesions are the leading cause of small bowel obstruction. Gastrografin transit time may allow for the selection of appropriate patients for non-operative management. Some studies have shown when the contrast does not reach the colon after a designated time it indicates complete intestinal obstruction that is unlikely to resolve with conservative treatment. When the contrast does reach the large bowel, it indicates partial obstruction and patients are likely to respond to conservative treatment. Other studies have suggested that the administration of water-soluble contrast is therapeutic in resolving the obstruction.
To determine the reliability of water-soluble contrast media and serial abdominal radiographs in predicting the success of conservative treatment in patients admitted with adhesive small bowel obstruction.Furthermore, to determine the efficacy and safety of water-soluble contrast media in reducing the need for surgical intervention and reducing hospital stay in adhesive small bowel obstruction.
The search was conducted using MESH terms: ''Intestinal obstruction'', ''water-soluble contrast'', "Adhesions" and "Gastrografin". The later combined with the Cochrane Collaboration highly sensitive search strategy for identifying randomised controlled trials and controlled clinical trials.
The appearance of water-soluble contrast in the colon on an abdominal X ray within 24 hours of its administration predicts resolution of an adhesive small bowel obstruction with a pooled sensitivity of 0.97, specificity of 0.96. The area under the curve of the summary ROC curve is 0.98. Six randomised studies dealing with the therapeutic role of gastrografin were included in the review, water-soluble contrast did not reduce the need for surgical intervention (OR 0.81, p = 0.3). Meta-analysis of four of the included studies showed that water-soluble contrast did reduce hospital stay compared with placebo (WMD= - 1.83) P<0.001.
AUTHORS' CONCLUSIONS: Published literature strongly supports the use of water-soluble contrast as a predictive test for non-operative resolution of adhesive small bowel obstruction. Although Gastrografin does not cause resolution of small bowel obstruction there is strong evidence that it reduces hospital stay in those not requiring surgery.
粘连是小肠梗阻的主要原因。泛影葡胺通过时间可用于选择适合非手术治疗的患者。一些研究表明,在规定时间后造影剂未到达结肠表明存在完全性肠梗阻,保守治疗不太可能使其缓解。当造影剂到达大肠时,则表明存在部分梗阻,患者可能对保守治疗有反应。其他研究表明,给予水溶性造影剂对解除梗阻具有治疗作用。
确定水溶性造影剂和系列腹部X线片在预测粘连性小肠梗阻患者保守治疗成功方面的可靠性。此外,确定水溶性造影剂在减少粘连性小肠梗阻手术干预需求和缩短住院时间方面的有效性和安全性。
检索使用了医学主题词:“肠梗阻”、“水溶性造影剂”、“粘连”和“泛影葡胺”。后者与Cochrane协作网用于识别随机对照试验和对照临床试验的高敏感性检索策略相结合。
1.纳入前瞻性研究以评估水溶性造影剂在粘连性小肠梗阻中的诊断潜力。2.选择随机临床试验以评估其治疗作用。
1.对涉及水溶性造影剂诊断作用的研究进行严格评价,并将数据表示为敏感性、特异性、阳性和阴性似然比。汇总结果并构建总结性ROC曲线。2.使用Mantel-Henszel检验,采用固定效应模型和随机效应模型对治疗性研究的数据进行荟萃分析。
在给予水溶性造影剂后24小时内,腹部X线片上结肠内出现水溶性造影剂预示粘连性小肠梗阻可缓解,汇总敏感性为0.97,特异性为0.96。总结性ROC曲线下面积为0.98。该综述纳入了6项关于泛影葡胺治疗作用的随机研究,水溶性造影剂并未减少手术干预需求(OR=0.81,p=0.3)。对其中4项纳入研究的荟萃分析表明,与安慰剂相比,水溶性造影剂确实缩短了住院时间(WMD=-1.83),P<0.001。
已发表的文献有力支持使用水溶性造影剂作为粘连性小肠梗阻非手术缓解的预测性检查。虽然泛影葡胺不能解除小肠梗阻,但有强有力的证据表明它可缩短不需要手术患者的住院时间。